title: Fractured DES with a patent coronary artery: clinical implications.
abstract: Recently, reports of stent fracture with focal restenosis have suggested that it is another mechanism of in-stent restenosis after implantation of sirolimus-eluting stents. However, the mechanism by which strut disruption occurs remains unknown. Current reports of in-stent restenosis suggest that fracture of drug-eluting stents is different from bare-metal stents, and can progress to restenosis and reocclusion. We report on a patient with a fractured stent in a patent coronary artery that progressed to diffuse neointimal hyperplasia presenting with acute myocardial infarction 2 years after stent placement.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, Yeungnam University Hospital, Daegu, South Korea.
authors.forename: Jong-Seon
authors.initials: JS
authors.lastname: Park
authors.forename: Dong-Gu
authors.initials: DG
authors.lastname: Shin
authors.forename: Young-Jo
authors.initials: YJ
authors.lastname: Kim
mesh_terms: D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000628:therapy*; D018450:Disease Progression; D016503:Drug Delivery Systems; D004868:Equipment Failure; D006801:Humans; D006965:Hyperplasia / Q000473:pathology; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology* / Q000473:pathology; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents / Q000009:adverse effects*; D017211:Treatment Failure; D017539:Tunica Intima / Q000473:pathology*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus